361 related articles for article (PubMed ID: 11221827)
1. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Towle MJ; Salvato KA; Budrow J; Wels BF; Kuznetsov G; Aalfs KK; Welsh S; Zheng W; Seletsky BM; Palme MH; Habgood GJ; Singer LA; Dipietro LV; Wang Y; Chen JJ; Quincy DA; Davis A; Yoshimatsu K; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2001 Feb; 61(3):1013-21. PubMed ID: 11221827
[TBL] [Abstract][Full Text] [Related]
2. Macrocyclic ketone analogues of halichondrin B.
Zheng W; Seletsky BM; Palme MH; Lydon PJ; Singer LA; Chase CE; Lemelin CA; Shen Y; Davis H; Tremblay L; Towle MJ; Salvato KA; Wels BF; Aalfs KK; Kishi Y; Littlefield BA; Yu MJ
Bioorg Med Chem Lett; 2004 Nov; 14(22):5551-4. PubMed ID: 15482922
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.
Dabydeen DA; Burnett JC; Bai R; Verdier-Pinard P; Hickford SJ; Pettit GR; Blunt JW; Munro MH; Gussio R; Hamel E
Mol Pharmacol; 2006 Dec; 70(6):1866-75. PubMed ID: 16940412
[TBL] [Abstract][Full Text] [Related]
4. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Kuznetsov G; Towle MJ; Cheng H; Kawamura T; TenDyke K; Liu D; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2004 Aug; 64(16):5760-6. PubMed ID: 15313917
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
Alday PH; Correia JJ
Biochemistry; 2009 Aug; 48(33):7927-38. PubMed ID: 19586046
[TBL] [Abstract][Full Text] [Related]
6. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
Jordan MA; Kamath K; Manna T; Okouneva T; Miller HP; Davis C; Littlefield BA; Wilson L
Mol Cancer Ther; 2005 Jul; 4(7):1086-95. PubMed ID: 16020666
[TBL] [Abstract][Full Text] [Related]
7. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
[TBL] [Abstract][Full Text] [Related]
8. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
[TBL] [Abstract][Full Text] [Related]
9. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
[TBL] [Abstract][Full Text] [Related]
10. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of halichondrin B analogues: modifications at C.30-C.38.
Wang Y; Habgood GJ; Christ WJ; Kishi Y; Littlefield BA; Yu MJ
Bioorg Med Chem Lett; 2000 May; 10(10):1029-32. PubMed ID: 10843209
[TBL] [Abstract][Full Text] [Related]
12. Novel 2-methoxyestradiol analogues with antitumor activity.
Tinley TL; Leal RM; Randall-Hlubek DA; Cessac JW; Wilkens LR; Rao PN; Mooberry SL
Cancer Res; 2003 Apr; 63(7):1538-49. PubMed ID: 12670902
[TBL] [Abstract][Full Text] [Related]
13. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Newman S
Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
[TBL] [Abstract][Full Text] [Related]
14. Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts.
Fodstad O; Breistøl K; Pettit GR; Shoemaker RH; Boyd MR
J Exp Ther Oncol; 1996 Mar; 1(2):119-25. PubMed ID: 9414395
[TBL] [Abstract][Full Text] [Related]
15. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.
Kuznetsov G; TenDyke K; Towle MJ; Cheng H; Liu J; Marsh JP; Schiller SE; Spyvee MR; Yang H; Seletsky BM; Shaffer CJ; Marceau V; Yao Y; Suh EM; Campagna S; Fang FG; Kowalczyk JJ; Littlefield BA
Mol Cancer Ther; 2009 Oct; 8(10):2852-60. PubMed ID: 19825803
[TBL] [Abstract][Full Text] [Related]
16. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
17. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
Mahboobi S; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Lyssenko A; Paper DH; Bürgermeister J; Böhmer FD; Fiebig HH; Burger AM; Baasner S; Beckers T
J Med Chem; 2001 Dec; 44(26):4535-53. PubMed ID: 11741473
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
Wang G; Peng F; Cao D; Yang Z; Han X; Liu J; Wu W; He L; Ma L; Chen J; Sang Y; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2013 Nov; 21(21):6844-54. PubMed ID: 23993668
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
Liu Z; Zhou Z; Tian W; Fan X; Xue D; Yu L; Yu Q; Long YQ
ChemMedChem; 2012 Apr; 7(4):680-93. PubMed ID: 22311585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
